Year | Detail |
1885-1948 |
Innovative beginnings |
1885 |
Albert Boehringer purchased a small tartar factory in Nieder-Ingelheim, now part of Ingelheim am Rhein. |
1893 |
Experiments were undertaken to produce citric acid, which resulted in the formation of lactic acid. After two years, the company registered its first patent for a new process for manufacturing lactic acid baking powder. |
1917 |
The research department was established on the initiative of the chemist Heinrich Wieland, a cousin of Albert Boehringer. This R&D department will be responsible for all research and development activities across the company’s acid, alkaloid, and pharmaceutical sectors. |
1933-1945 |
The National Socialism period also affected Boehringer Ingelheim as a manufacturing company. Some of its seizure of power included delayed production of consumer goods, import limitations, and foreign currency restrictions. |
1945 |
The CELA Landwirtschaftliche Chemikalien GmbH (Agricultural Chemicals Ltd.) was founded to manufacture pesticides that help farmers safeguard their crops against the potato beetle plague |
|
|
1948-1990 |
Going global |
1948 |
The first foreign subsidiary, Bender & Co. GmbH, was established three years after the end of the Second World War. |
1950 |
Boehringer Ingelheim collaborated with Pfizer & Co., the American pharmaceutical company in the field of antibiotics. |
1955 |
Boehringer Ingelheim received an offer from Pfizer & Co. to sell and distribute Terramycin antibiotics. This development marks the beginning of the animal health sector in Boehringer Ingelheim. |
1961 |
The Institute for Pharmaceutical Research, focused on virology and pharmacology, was founded in Vienna. |
1977 |
The Boehringer Ingelheim Foundation was established to promote biology, chemistry, medicine, and pharmaceutical science research. |
1989 |
The company launched Alveofact, a surfactant substitute for respiratory distress syndrome in newborns. |
|
|
1990-2024 |
Value through Innovation |
1993 |
The German pharmaceutical business with two sites in Ingelheim and Biberach was under one joint management. |
2000 |
Boehringer Ingelheim Center sets new standards in Ingelheim, which include administrative and corporate functions at the heart of company operations. |
2003 |
Boehringer Ingelheim invested approximately $288.4 million to expand its biopharmaceutical active ingredient production facilities in Biberach. |
2004 |
Boehringer Ingelheim acquired STEAG Microparts GmbH, a micro-technology company in Germany, from STEAG AG Essen. |
2011 |
Boehringer Ingelheim and Eli Lilly received authorization from the European Commission to market Trajenta (linagliptin), a drug used to treat adults with type 2 diabetes. |
2019 |
Boehringer Ingelheim partnered with Lupin Ltd. to develop and commercialize a novel Oncology drug to treat KRAS-driven cancers. Under this agreement, the company will strengthen its portfolio for patients with lung and gastrointestinal cancers. |
2023 |
Boehringer Ingelheim signed an agreement with IBM to utilize its foundation model technologies to discover novel candidate antibodies for developing efficient therapeutics. |
2023 |
Boehringer Ingelheim unveiled its advanced Biologicals Development Center (BDC) in Biberach an der Riß, Germany. With an investment of 378.6 million, the company significantly enhances its innovation power and development of biopharmaceutical development capabilities in Germany. |
2024 |
Boehringer Ingelheim opened its new biogas power plant in Ingelheim site, Germany. The new biomass power plant minimizes the CO2 emissions produced by the energy generated at the plant by 50%. |